Acute Kidney Injury Prevention

Acute kidney injury (AKI) affects 10-15% of hospitalized patients and up to 50% of ICU patients, with even modest serum creatinine elevations associated with increased mortality. Contrast-induced nephropathy (CIN) was identified as a major iatrogenic cause, and N-acetylcysteine (NAC) became widely adopted for prevention based on the Tepel 2000 study showing an 89% relative risk reduction in contrast nephropathy. NAC's low cost, perceived safety, and dramatic initial results led to near-universal adoption despite small sample sizes and inconsistent follow-up studies. Simultaneously, intravenous fluid hydration with saline or bicarbonate was established as a prophylactic strategy, though the optimal fluid type and volume remained debated for years.

The PRESERVE trial (2018), a landmark large-scale RCT, definitively debunked both NAC and sodium bicarbonate for contrast-associated AKI prevention. In 5177 high-risk patients undergoing angiography, neither NAC (vs placebo) nor sodium bicarbonate (vs normal saline) reduced the composite of death, dialysis, or persistent creatinine elevation at 90 days. The results were unequivocal: NAC provided no kidney protection beyond that of saline hydration, and bicarbonate offered no advantage over saline. This trial ended two decades of clinical practice based on inadequate evidence and highlighted how small, underpowered trials with surrogate endpoints can drive widespread adoption of ineffective treatments. The field pivoted from pharmacological prophylaxis toward fluid optimization and risk avoidance strategies.

KDIGO AKI care bundles — a package of supportive measures including hemodynamic optimization, avoidance of nephrotoxins, glycemic control, and discontinuation of ACE inhibitors/ARBs in acute illness — emerged as the evidence-based approach to AKI prevention. The BigpAK trial showed that implementing KDIGO bundles triggered by novel AKI biomarkers (NGAL, TIMP-2/IGFBP7) in high-risk cardiac surgery patients reduced AKI severity. Electronic AKI alert systems (e-alerts) that notify clinicians of early creatinine rises were tested in multiple studies. The NGAL, KIM-1, and TIMP-2*IGFBP7 (NephroCheck) biomarkers enabled earlier AKI detection, potentially allowing intervention before creatinine rises. The concept shifted from preventing a specific cause (contrast) to a systems approach preventing AKI from all causes.

KDIGO AKI guidelines (2012, updated 2024) provide a comprehensive prevention and management framework. For contrast-associated AKI, guidelines now recommend volume expansion with isotonic saline (not bicarbonate, per PRESERVE) and minimizing contrast volume; NAC is no longer recommended. For general AKI prevention, KDIGO bundles include: optimize volume status and hemodynamics, avoid nephrotoxic drugs when possible, monitor serum creatinine and urine output, avoid hyperglycemia, and consider alternatives to radiocontrast. The AKI staging system (stages 1-3 based on creatinine and urine output criteria) is universally adopted for classification and guiding management intensity.

AKI prevention has evolved from a focus on contrast nephropathy to a comprehensive approach addressing all AKI causes. The field increasingly recognizes that contrast-associated AKI was overdiagnosed — many creatinine rises attributed to contrast were actually caused by the underlying condition prompting the imaging study. Novel biomarkers (NGAL, KIM-1, TIMP-2*IGFBP7) enable AKI detection 12-48 hours before creatinine rises, creating a therapeutic window for intervention. Electronic AKI e-alert systems are being deployed in hospital EHR platforms worldwide, though evidence for their impact on outcomes remains mixed. The most promising frontier is biomarker-guided KDIGO bundle implementation, where AKI biomarker elevation triggers a standardized prevention package before clinical AKI manifests. Artificial intelligence models predicting AKI 48 hours in advance are being validated and may enable true preemptive prevention.